SPL 0.00% 8.9¢ starpharma holdings limited

Sale of DEP platform?

  1. 4,827 Posts.
    lightbulb Created with Sketch. 249
    I believe the CEO is pursuing sale of the DEP cancer drug platform the sale will include all current in house drugs along with a large patent portfolio and listed applications. The sale will create a large cash chest for Starpharma to pursue their existing products and applications, the CEO hinted at this possibility in a recent interview. As far as potential value of moneyterizing the platform I am not sure something approaching $400m I would guess. This is just my opinion and not financial advice.
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Last
8.9¢
Change
0.000(0.00%)
Mkt cap ! $36.67M
Open High Low Value Volume
9.0¢ 9.3¢ 8.9¢ $132.1K 1.454M

Buyers (Bids)

No. Vol. Price($)
3 121499 8.9¢
 

Sellers (Offers)

Price($) Vol. No.
9.0¢ 3000 1
View Market Depth
Last trade - 16.10pm 25/06/2024 (20 minute delay) ?
SPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.